Products
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Merck, Inc.
🇵🇭
Philippines
Country
🇵🇭
Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News
Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)
Phase 2
Terminated
Conditions
Hypopnea Syndrome
Sleep Apnea, Obstructive
Excessive Daytime Sleepiness
Subscribe
First Posted Date
2008-02-21
Last Posted Date
2015-05-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
125
Registration Number
NCT00620659
Subscribe
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Subscribe
First Posted Date
2008-02-20
Last Posted Date
2015-09-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
26
Registration Number
NCT00618995
Subscribe
Antihypertensive Response to Losartan and Genetic Polymorphisms
Not Applicable
Completed
Conditions
Hypertension
Interventions
Drug: losartan potassium
Subscribe
First Posted Date
2008-02-18
Last Posted Date
2009-07-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
800
Registration Number
NCT00617877
Subscribe
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
Phase 2
Terminated
Conditions
Sarcoma, Ewing's
Osteosarcoma
Peripheral Neuroectodermal Tumor
Interventions
Biological: robatumumab
Subscribe
First Posted Date
2008-02-18
Last Posted Date
2018-08-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
219
Registration Number
NCT00617890
Subscribe
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
Phase 3
Completed
Conditions
Atherosclerosis
Ischemia
Myocardial Infarction
Cerebrovascular Accident
Interventions
Drug: Vorapaxar 2.5 mg
Drug: Placebo
Subscribe
First Posted Date
2008-02-15
Last Posted Date
2018-09-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
258
Registration Number
NCT00617123
Subscribe
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Biological: dalotuzumab
Biological: cetuximab
Drug: irinotecan hydrochloride
Drug: placebo
Subscribe
First Posted Date
2008-02-13
Last Posted Date
2018-08-08
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
558
Registration Number
NCT00614393
Subscribe
Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
Phase 2
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Drug: MK-8777
Drug: Placebo
Subscribe
First Posted Date
2008-02-08
Last Posted Date
2018-10-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
67
Registration Number
NCT00610441
Subscribe
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
Phase 3
Completed
Conditions
Insomnia
Interventions
Drug: Org 50081
Subscribe
First Posted Date
2008-02-08
Last Posted Date
2018-10-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
346
Registration Number
NCT00610675
Subscribe
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Phase 2
Completed
Conditions
Depression
Interventions
Drug: MK-8777
Drug: Placebo
Subscribe
First Posted Date
2008-02-08
Last Posted Date
2018-11-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
54
Registration Number
NCT00610649
Subscribe
Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
Phase 4
Terminated
Conditions
Breast Neoplasms
Interventions
Drug: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Subscribe
First Posted Date
2008-01-30
Last Posted Date
2017-06-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
25
Registration Number
NCT00604968
Subscribe
Prev
1
147
148
149
150
151
200
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy